Eli Lilly and Company announced plans to add two more cost-saving options to its suite of solutions for people who use Lilly insulin by introducing lower-priced versions of Humalog® Mix75/25™ KwikPen® (insulin lispro protamine and insulin lispro injectable suspension 100 units/mL) and Humalog® Junior KwikPen® (insulin lispro injection 100 units/mL). Both insulins will have 50% lower list prices compared to the branded versions and will be available by mid-April. Lilly's first lower-priced insulin, Insulin Lispro Injection (100 units/mL), was made available in May 2019 at a 50% lower list price than Humalog® (insulin lispro injection 100 units/mL). In November 2019, more than 67,000 people filled prescriptions for Insulin Lispro Injection, and approximately 10% of people using Humalog have transitioned to the lower-priced option. Insulin Lispro Injection is now distributed by all major U.S. wholesalers and can be ordered by any pharmacy. Lilly will begin negotiations immediately with wholesalers and payers to make these additional lower-priced insulins available. Combined, Humalog U-100, Humalog Mix75/25, and Humalog Junior KwikPen make up more than 90% of prescriptions written for a Lilly mealtime insulin. With a lower-priced version of each available, the vast majority of people using a Humalog formulation will have an option that may reduce their out-of-pocket costs. Humalog Mix75/25 is one of Lilly's most prescribed insulins, with nearly 600,000 prescriptions filled in the last 12 months. These insulins are identical molecules to the branded versions and may be substituted at the pharmacy counter. Because most insurance plans provide affordable copays for chronic medicines that are much lower than the list price, people should ask their pharmacist whether these options reduce their out-of-pocket cost.